Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo...

Area of Science:

• Neurology
• Immunology

Background:

• Intravenous immunoglobulin (IVIG) has shown efficacy in relapsing-remitting multiple sclerosis (MS).
• Evidence for IVIG's benefit in chronic progressive MS forms is limited and inconclusive from placebo-controlled studies.

Purpose of the Study:

• To investigate the efficacy of IVIG in primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS).
• To assess IVIG's impact on disease progression and neurological function in chronic progressive MS.

Main Methods:

• A 24-month randomized, placebo-controlled trial involving 231 patients stratified into PPMS and SPMS groups.
• Patients received monthly IVIG (0.4 g/kg) or placebo.
• Primary endpoints included time to sustained disability progression (Expanded Disability Status Scale - EDSS) and improvement in neurological function.

Main Results:

• In the combined intention-to-treat (ITT) population, IVIG significantly prolonged the time to sustained progression (74 vs. 62 weeks, P=0.0406).
• IVIG treatment showed a significant reduction in sustained progression in PPMS patients (P=0.016) and a trend in the combined per-protocol population (P=0.036).
• No significant improvement in neurological functions or other secondary endpoints was observed across groups, although PPMS patients showed a slight favorable effect on their best EDSS score.

Conclusions:

• Monthly IVIG infusions may delay disease progression in patients with PPMS.
• A trend favoring IVIG treatment for disease progression was noted in SPMS patients.
• IVIG was generally well-tolerated, with a small percentage of patients withdrawing from the study.